IPP Bureau
Korea’s MFDS completes inspection at Concord Biotech's Dholka unit
By IPP Bureau - February 21, 2025
The inspection was successfully completed
European Commission approves Biocon Biologics' Ustekinumab Biosimilar
By IPP Bureau - February 21, 2025
YESINTEK, is intended for the treatment of adults and children with plaque psoriasis and adults with psoriatic arthritis or Crohn's disease
Lupin receives EIR from USFDA for its Somerset manufacturing facility
By IPP Bureau - February 21, 2025
the inspection conducted from January 27 to January 31, 2025
USFDA issues Form-483 for Piramal Pharma's facility at Turbhe
By IPP Bureau - February 21, 2025
Observations are largely around improvement of procedures and practices
Orchid Pharma's Alathur API facility successfully completes USFDA inspection
By IPP Bureau - February 20, 2025
The Alathur facility specializes in the production of Cephalosporin antibiotics
Boehringer's zongertinib receives Priority Review from USFDA for the treatment of HER2 mutant advanced non-small cell lung cancer
By IPP Bureau - February 20, 2025
Zongertinib would be the first orally administered, targeted therapy for previously treated patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC), if approved
Innocan Pharma granted first patent in India for its Liposomal CBD Injection
By IPP Bureau - February 20, 2025
Innovative chronic pain treatment receives IP protection in India's $55 billion pharmaceutical market
IMCD showcases ‘Skinification’ trend at HPCI India 2025
By IPP Bureau - February 19, 2025
IMCD India’s innovative formulations bring the Skinification trend to life with cutting-edge solutions across beauty and personal care
Merck’s Welireg receives European approval for two indications
By IPP Bureau - February 19, 2025
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
KIMS partners with UAIMS Hospital
By IPP Bureau - February 19, 2025
This strategic partnership will also enable KIMS to exercise call option (not an obligation) to acquire majority stake in UAIMS Hospital in the coming years
Sun Pharma amongst top 5% of global pharmaceutical companies in S&P Global Sustainability Yearbook 2025
By IPP Bureau - February 19, 2025
This Yearbook aims to distinguish those companies that have demonstrated strengths in corporate sustainability
Lupin receives “A-” leadership rating from CDP in climate change and water security
By IPP Bureau - February 19, 2025
This rating reflects Lupin's leadership in environmental transparency and performance
EyeQ upgrades eye care facility in Surat
By IPP Bureau - February 18, 2025
Theatre (OTs) dedicated to cataract, LASIK, and retina treatments added to meet the growing demand
Health Minister inaugurates Second AIIMS Oncology Conclave at NCI-AIIMS, Jhajjar
By IPP Bureau - February 18, 2025
Dr. Prabhavathi. R joins HEJJE
By IPP Bureau - February 18, 2025
Dr. Prabhavathi brings over 14 years of unparalleled experience in pediatrics and a specialized focus on neurodevelopmental disorders
